Hematology最新文献_第10页

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia. 病例报告：Venetoclax 联合阿扎胞苷治疗急性未分化白血病。

IF 1.9 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2023-12-14 DOI: 10.1080/16078454.2023.2293494

Yu Cui, Ruihua Mi, Lin Chen, Lin Wang, Dongbei Li, Xudong Wei

{"title":"Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia.","authors":"Yu Cui, Ruihua Mi, Lin Chen, Lin Wang, Dongbei Li, Xudong Wei","doi":"10.1080/16078454.2023.2293494","DOIUrl":"https://doi.org/10.1080/16078454.2023.2293494","url":null,"abstract":"Objectives: Acute undifferentiated leukemia (AUL) is a clinical rare leukemia with an overall poor prognosis. Currently, there are no well-established treatment guidelines for AUL, further exploration of optimal treatment options is now required.Methods: We report an AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital and we present the clinical features. In addition, we conducted a literature review.Results: The \"VA\" scheme combines agents Venetoclax and Azacitidine that have synergistic therapeutic effect with a tolerable safety profile. There is no previous report of the \"VA\" scheme employed in AUL treatment. An AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital. The \"VA\" scheme was administrated, and complete remission (CR) was achieved at the end of the first cycle. The patient then underwent HLA-identical sibling allogeneic hematopoietic stem cell transplantation.Discussion: The \"VA\" scheme has been extensively used in AML treatment, but its application in AUL treatment has not yet been reported. This study is the first to report an AUL patient treated with the \"VA\" scheme and achieved CR. Our result preliminarily suggested the effectiveness and safety of the \"VA\" scheme in AUL treatment, but validation is required in more clinical samples. The \"VA\" scheme provides a new treatment option for AUL patients and deserves further clinical promotion.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2293494"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortality among US veterans with a physician-documented diagnosis of pyruvate kinase deficiency. 经医生确诊患有丙酮酸激酶缺乏症的美国退伍军人的死亡率。

IF 1.9 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2023-12-14 DOI: 10.1080/16078454.2023.2290746

Erin Zagadailov, Hanny Al-Samkari, Audra N Boscoe, Bryan McGee, Sherry Shi, Dendy Macaulay, Lizheng Shi, Viviana Garcia-Horton

{"title":"Mortality among US veterans with a physician-documented diagnosis of pyruvate kinase deficiency.","authors":"Erin Zagadailov, Hanny Al-Samkari, Audra N Boscoe, Bryan McGee, Sherry Shi, Dendy Macaulay, Lizheng Shi, Viviana Garcia-Horton","doi":"10.1080/16078454.2023.2290746","DOIUrl":"https://doi.org/10.1080/16078454.2023.2290746","url":null,"abstract":"Real-world studies of pyruvate kinase (PK) deficiency and estimates of mortality are lacking. This retrospective observational study aimed to identify patients with PK deficiency and compare their overall survival (OS) to that of a matched cohort without PK deficiency. Patients with ≥1 diagnosis code related to PK deficiency were selected from the US Veterans Health Administration (VHA) database (01/1995-07/2019); patients with a physician-documented diagnosis were included (PK deficiency cohort; index: date of first diagnosis code related to PK deficiency). Patients in the PK deficiency cohort were matched 1:5 to patients from the general VHA population (non-PK deficiency cohort; index: random visit date during match's index year). OS from index was compared between the two cohorts. Eighteen patients in the PK deficiency cohort were matched to 90 individuals in the non-PK deficiency cohort (both cohorts: mean age 57 years, 94% males; median follow-up 6.0 and 8.0 years, respectively). At follow-up, patients in the non-PK deficiency cohort had significantly longer OS than the PK deficiency cohort (median OS: 17.1 vs. 10.9 years; hazard ratio: 2.3; p = 0.0306). During their first-year post-index, 75% and 40% of the PK deficiency cohort had laboratory-confirmed anemia and iron overload, respectively. Among patients who died, cause of death was highly heterogeneous. These results highlight the increased risk of mortality and substantial clinical burden among patients with PK deficiency. While the intrinsic characteristics of the VHA database may limit the generalizability of the results, this is the first real-world study to characterize mortality in patients with PK deficiency.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2290746"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global research trends in traditional Chinese medicine therapy for acute leukemia: a comprehensive visualization and bibliometric analysis. 中医药治疗急性白血病的全球研究趋势：综合可视化和文献计量分析。

IF 2 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-11-12 DOI: 10.1080/16078454.2024.2427896

Wenwen Zhang, Kaili Zhang, Yuqing Feng, Gaofeng Zhang

{"title":"Global research trends in traditional Chinese medicine therapy for acute leukemia: a comprehensive visualization and bibliometric analysis.","authors":"Wenwen Zhang, Kaili Zhang, Yuqing Feng, Gaofeng Zhang","doi":"10.1080/16078454.2024.2427896","DOIUrl":"10.1080/16078454.2024.2427896","url":null,"abstract":"Background: The application of traditional Chinese medicine (TCM) therapy to acute leukemia has been intensively investigated. However, the bibliometric analysis in this field has not been performed. This bibliometric study aimed to comprehensively analyze the research trends and active areas of TCM therapy for acute leukemia from 2000 to 2023.Methods: We searched articles and reviews published between 2000 and 2023 that discussed TCM in acute leukemia from the Web of Science Core Collection (WoSCC). Knowledge mapping and bibliometric analysis were conducted using VOSviewer, CiteSpace software, and R-bibliometrix.Results: A total of 1,099 articles were included, with China, the United States, and Korea contributing the most papers. Most papers were published in the Journal of Ethnopharmacology. Meanwhile, China saw a steady increase in the number of publications. The three leading institutions that made outstanding contributions were the China Medical University, the Chinese Academy of Sciences, and the China Academy of Chinese Medical Sciences. Efferth Thomas, Liu Wei, and Liu Jie were the top three productive authors, with Efferth T receiving the most co-citations. The most frequently cited reference was Shen ZX (1997). In the analysis of keywords co-occurrence, 'survival,' 'risk factors,' 'nanoparticles,' and 'metabolism' are the active research topics.Conclusion: This bibliometric study provides researchers with a comprehensive overview and significant value in understanding the development of TCM in acute leukemia treatment.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2427896"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The genotype and phenotype analysis in 3 cases with the rare genotype of HBB:c.316-146T > G. 3例罕见基因型为HBB:c.316-146T > G的病例的基因型和表型分析。

IF 2 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/16078454.2024.2433188

Yan-Bin Cao, Yi-Yuan Ge, Long-Xu Xie, Guang-Kuan Zeng, Bai-Ru Lai, Xiao-Hua Yu, Jian-Lian Liang, Li-Ye Yang

{"title":"The genotype and phenotype analysis in 3 cases with the rare genotype of HBB:c.316-146T > G.","authors":"Yan-Bin Cao, Yi-Yuan Ge, Long-Xu Xie, Guang-Kuan Zeng, Bai-Ru Lai, Xiao-Hua Yu, Jian-Lian Liang, Li-Ye Yang","doi":"10.1080/16078454.2024.2433188","DOIUrl":"https://doi.org/10.1080/16078454.2024.2433188","url":null,"abstract":"Objectives: To explore the genotypic and phenotypic characteristics of HBB: c.316-146T > G carriers in China.Methods: The blood routine parameters and hemoglobin electrophoresis data of carriers were analyzed using PCR combined with reverse dot blot (RDB), gap-PCR, and DNA sequencing.Results: The blood routine parameters of all these three cases were MCV < 82fl and MCH < 27pg, and hemoglobin electrophoresis showed HbA2 ≥ 4.60%. Genetic testing results: two cases were heterozygous mutations of HBB:c.316-146T > G, the other one was heterozygous mutation of HBB:c.316-146T > G combined with -SEA deletion.Conclusion: The hematological phenotype of HBB:c.316-146T > G mutation carriers is similar to that of common β+ heterozygous mutations, presenting with hypochromic, microcytic red cell indices. If the hematological phenotype does not match the results of genetic testing, further detection techniques such as Sanger sequencing, MLPA, next-generation sequencing (NGS), etc. are required to avoid missing rare or novel mutation types.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2433188"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venous thromboembolism in patients with hairy cell leukemia. 毛细胞白血病患者的静脉血栓栓塞。

IF 2 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1080/16078454.2024.2431405

Lauren Peralta, Muneer Khan, Marcelle G Meseeha, Julie L Richards, Joyson Poulose, Giampaolo Talamo

{"title":"Venous thromboembolism in patients with hairy cell leukemia.","authors":"Lauren Peralta, Muneer Khan, Marcelle G Meseeha, Julie L Richards, Joyson Poulose, Giampaolo Talamo","doi":"10.1080/16078454.2024.2431405","DOIUrl":"10.1080/16078454.2024.2431405","url":null,"abstract":"Background: Hairy cell leukemia (HCL) is rare leukemia of mature B cells, accounting for 2% of all lymphoid neoplasms. Although the association of venous thromboembolism (VTE) with cancer is well established, there is no systematic study describing VTE in HCL.Aim: To analyze prevalence and risk factors associated with VTE in HCL patients.Methods: We retrospectively reviewed data from the medical records of 56 consecutive HCL patients evaluated in our Hematology/Oncology clinic between 1998 and 2023.Results: The median age at diagnosis was 59 years (range, 37-94), and 49 patients (87%) were male. With a median follow-up of 122 months (1-291), we identified 11 episodes of VTE in 8 (14%) HCL patients: pulmonary embolism (PE) (5 cases) with or without concurrent deep venous thrombosis (DVT), and DVT alone (6 cases). All thrombotic episodes occurred after the diagnosis of HCL, or at the same time of it, as presenting clinical manifestation of the HCL. Risk factors for VTE other than cancer were identified in only 3 patients.Conclusion: Our study found a high incidence of VTE in patients with HCL, mostly in the absence of other provoking factors, suggesting that this hematologic malignancy is associated with an underlying thrombophilic state.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2431405"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study. 日本治疗血友病 A 的 turoctocog alfa 的长期实际安全性和有效性：一项多中心、非干预性、上市后研究的结果。

IF 1.9 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-02-20 DOI: 10.1080/16078454.2024.2316540

Azusa Nagao, Ayumi Deguchi, Keiji Nogami

{"title":"Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.","authors":"Azusa Nagao, Ayumi Deguchi, Keiji Nogami","doi":"10.1080/16078454.2024.2316540","DOIUrl":"10.1080/16078454.2024.2316540","url":null,"abstract":"Objectives: To assess the safety and effectiveness of turoctocog alfa in previously treated patients (PTPs) and previously untreated patients (PUPs) with haemophilia A in a real-world setting in Japan.Methods: This multicentre, non-interventional, post-marketing study recruited patients with haemophilia A who initiated treatment with turoctocog alfa from 18 sites (08/2014-12/2018). The primary endpoint was adverse events (AEs) during the 2-year study period.Results: The safety and effectiveness analysis set included 39 patients. In total, 13 (33.3%) patients reported ≥1 AE; incidence rate was 60.4 events/100 patient-years of exposure (PYE). Treatment was withdrawn in two cases: pruritus in a PTP and factor VIII inhibitor development in a PUP. Inhibitor development occurred in 2.6% of all patients, with an incidence rate of 3.8 events/100 PYE. The rate of inhibitor development was 0%, 25% and 20% in PTPs, PUPs and PUPs with severe type, respectively. The haemostatic success rate was 91.4% for 383 bleeding episodes and 85.7% for 14 surgeries. The negative binomial annualised bleeding rate for the prophylaxis regimen was 6.19 episodes/year (95% CI, 3.69-10.38). The mean (SD) total consumption of turoctocog alfa (n = 34; excluding FVIII inhibitors) was 5,382.6 (7,180.1) IU/kg/year/patient; consumption was 4,133.1 (1,452.4) IU/kg/year/patient for prophylaxis.Discussion: The effectiveness and safety profiles were comparable to those observed in other turoctocog alfa trials; effectiveness analysis and consumption were not affected by treatment regimens.Conclusion: Long-term use of turoctocog alfa therapy in clinical practice posed no newly identified safety issues and was effective for prophylaxis and treatment of bleeds in patients with haemophilia A in Japan.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2316540"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A retrospective study of prognostic factors and treatment outcome in advanced-stage Mycosis Fungoides and Sezary Syndrome. 对晚期真菌病和塞扎里综合征预后因素和治疗效果的回顾性研究。

IF 2 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-07-08 DOI: 10.1080/16078454.2024.2366631

Zhuo-Fan Xu, Hongyun Chen, Yuehua Liu, Wei Zhang, Hongzhong Jin, Jie Liu

{"title":"A retrospective study of prognostic factors and treatment outcome in advanced-stage Mycosis Fungoides and Sezary Syndrome.","authors":"Zhuo-Fan Xu, Hongyun Chen, Yuehua Liu, Wei Zhang, Hongzhong Jin, Jie Liu","doi":"10.1080/16078454.2024.2366631","DOIUrl":"https://doi.org/10.1080/16078454.2024.2366631","url":null,"abstract":"Background: Mycosis fungoides (MF) and Sezary Syndrome (SS) comprise over half of all Cutaneous T-cell lymphoma diagnoses. Current risk stratification is largely based on TNMB staging, few research investigated the prognostic value of clinical exams. Current systemic therapy for advanced disease includes immunomodulatory drugs, chemotherapy, and HADC inhibitors. Few clinical trials or retrospective research compared the efficacy of different drugs.Method: Here, we performed a retrospective analysis of prognostic factors and treatment outcomes of 92 patients diagnosed with MF/SS at the Peking Union Medical College Hospital from 2013-2023.Results: Cox regression analysis identified that age ≥ 50 years, WBC ≥ 8 × 109/L, serum LDH ≥ 250U/L, β2-MG ≥ 4.50 mg/L, and stage IV were associated with reduced overall survival, age ≥ 50 years, serum LDH ≥ 250U/L and stage IV were associated with reduced progression free survival. Kaplan-Meier analysis established that immunomodulatory therapy was associated with longer progression free survival.Conclusion: These results suggested new factors in predicting prognosis and selecting appropriate treatments in patients with advanced MF/SS.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2366631"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mistakes in the management of iron deficiency anaemia: a narrative review. 缺铁性贫血管理中的错误：叙述性综述。

IF 2 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-08-07 DOI: 10.1080/16078454.2024.2387987

Madunil Anuk Niriella, Hiruni Jayasena, Achini Withanachchi, Anuja Premawardhena

引用次数: 0

Causal relationship between branched-chain amino acids and leukemia risk: insights from a two-sample Mendelian randomization study.

IF 2 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-12-11 DOI: 10.1080/16078454.2024.2433904

Shupeng Chen, Guilian He, Meiling Zhang, Nana Tang, Yingjian Zeng

{"title":"Causal relationship between branched-chain amino acids and leukemia risk: insights from a two-sample Mendelian randomization study.","authors":"Shupeng Chen, Guilian He, Meiling Zhang, Nana Tang, Yingjian Zeng","doi":"10.1080/16078454.2024.2433904","DOIUrl":"https://doi.org/10.1080/16078454.2024.2433904","url":null,"abstract":"Background: Branched-chain amino acids (BCAAs), including leucine, isoleucine, and valine, are essential amino acids involved in protein synthesis, energy metabolism, and immune regulation. While BCAAs are known to influence cancer biology, their role in leukemia remains unclear. This study employs Mendelian randomization (MR) analysis to explore the causal relationship between BCAA levels and four leukemia subtypes: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).Methods: Data from genome-wide association studies (GWAS) were used to select single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) for BCAA levels. The inverse-variance weighted (IVW) method served as the primary analytical approach, with heterogeneity assessed via Cochran's Q test and pleiotropy through MR-Egger intercept. Sensitivity analysis was performed using leave-one-out analysis.Results: A significant inverse association was observed between total BCAA levels, leucine, valine, and ALL risk. Total BCAA levels showed an odds ratio (OR) of 0.16 (95% CI: 0.05-0.54, p=0.003), leucine 0.17 (95% CI: 0.04-0.61, p=0.007), and valine 0.21 (95% CI: 0.07-0.61, p=0.004). No significant associations were found for AML, CLL, or CML.Conclusion: This study suggests that BCAAs, particularly leucine and valine, may protect against ALL, offering insights into leukemia metabolic regulation and potential targets for prevention and therapy.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2433904"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera. 较高的JAK2V617F等位基因负担可能是年轻的多发性红细胞症患者发生出血事件的风险因素。

IF 2 4区医学

Hematology Pub Date : 2024-12-01 Epub Date: 2024-11-15 DOI: 10.1080/16078454.2024.2427905

Chiho Furuya, Yoshinori Hashimoto, Soji Morishita, Yasutaka Fukuda, Tadaaki Inano, Tomonori Ochiai, Shuichi Shirane, Yoko Edahiro, Marito Araki, Miki Ando, Norio Komatsu

{"title":"A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera.","authors":"Chiho Furuya, Yoshinori Hashimoto, Soji Morishita, Yasutaka Fukuda, Tadaaki Inano, Tomonori Ochiai, Shuichi Shirane, Yoko Edahiro, Marito Araki, Miki Ando, Norio Komatsu","doi":"10.1080/16078454.2024.2427905","DOIUrl":"https://doi.org/10.1080/16078454.2024.2427905","url":null,"abstract":"Objectives: Hemorrhagic events are a rare but potentially fatal complication in patients with polycythemia vera (PV).Methods: We analyzed the characteristics of hemorrhagic events in 267 patients with PV.Results: A median follow-up of 4.8 years revealed that 23 (8.6%) hemorrhagic events occurred. Significantly more hemorrhagic events occurred in younger patients aged below 60 years (n = 72) than in older patients aged 60 years or above (n = 191) (n = 12 [16.7%] vs. n = 11 [5.8%], respectively, P = 0.012). In univariate analysis among the younger patients, white blood cell (WBC) count ≥ 15 × 109/L (hazard ratio [HR] = 7.746, 95% confidence interval [CI] 2.082-28.830, P = 0.002), palpable splenomegaly (HR = 5.629, 95% CI 1.193-26.550, P = 0.029), and JAK2V617F allele burden ≥ 80% (HR = 22.850, 95% CI 2.885-181.00, P = 0.003) were associated with an increased risk of hemorrhagic events. In multivariate analysis, JAK2V617F allele burden ≥ 80% (HR = 9.394, 95% CI 1.046-84.380, P = 0.046) was a significant risk factor.Conclusions: There is an increased risk of hemorrhagic events after diagnosis in younger PV patients with a high JAK2V617F allele burden, high WBC count or palpable splenomegaly. It is important to consider treatment options that aim to avoid hemorrhagic events by reducing the JAK2V617F allele burden in younger PV patients.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2427905"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0